Although PARP inhibitors are generally well-tolerated, numerous clinical trials have reported AEs, including anemia, fatigue, gastrointestinal symptoms, and hematological adverse events, likely due to the direct target of PARP1 and PARP2 (62). The gene discussed is PARP1; the disease is anemia.